GLP‐1 receptor analogues (GLP1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is), which modify the course of DKD independently of their antihyperglycaemic properties, may improve CKD outcomes for people with obesity and/or T2DM.11, 12. The gene discussed is GLP1R; the disease is Obesity.